September 16, 2022
Kyowa Kirin said on September 15 that it has filed Lumicef (brodalumab), an anti-interleukin-17 (IL-17) receptor A antibody, for an additional indication of palmoplantar pustulosis (PPP) in Japan. The filing is based on data from a Japanese PIII trial covering...read more